USE OF ATAZANAVIR IN HIV-INFECTED WOMEN DURING PREGNANCY


Cite item

Full Text

Abstract

The paper gives the currently available scientific data on the pharmacokinetics, tolerability, and safety ofatazanavir for pregnant women and their fetus/neonate and on the efficacy of the drug used as part in various highly active antiretroviral therapy regimens in HIV-infected women during pregnancy.

Full Text

Restricted Access

About the authors

L. Yu AFONINA

Republican Clinical Infectious Hospital, Ministry of Health and Social Development of Russia, Saint-Petersburg

Email: alarissa@ridh.spb.ru, alarissa-ridh@rambler.ru

Е. Е VORONIN

Republican Clinical Infectious Hospital, Ministry of Health and Social Development of Russia, Saint-Petersburg

Е. М MUKHINA

Republican Clinical Infectious Hospital, Ministry of Health and Social Development of Russia, Saint-Petersburg

Yu. A FOMIN

Republican Clinical Infectious Hospital, Ministry of Health and Social Development of Russia, Saint-Petersburg

References

  1. Centers for disease control and prevention (CDC). Achievements in public health. Reduction in perinatal transmission of HIV-infection United States, 1985-2005. Morb. Mortal Wkly Rep. 2006; 55 (21): 592-597.
  2. Townsend C.L., Cortina-Borja M., Peckham C.S. et al. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS. 2008; 22 (8): 973-981.
  3. Panel on treatment of HIV-infected pregnant women and prevention of perinatal transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. May 24, 2010: 1-117. Available at http://aidsinfo.nih.gov/ ContentFiles/PerinatalGL.pdf
  4. Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of health and human services. December 1, 2009: 1-161. Available at http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf.
  5. Бартлетт Дж., Галлант Дж., Фам П. Клинические аспекты ВИЧ-инфекции 2009-2010. М.: РВалент, 2010. Available at http://www.eurasiahealth.org/attaches/82168/ MMHIV10_Final.pdf
  6. Хоффман К., Рокштро Ю.К. Лечение ВИЧ-инфекции 2009. М.: Р.Валент, 2010. Available at http://www.eurasiahealth. org/attaches/82169/HIV-2009_Rus.pdf
  7. Бартлетт Дж. Карманный справочник по лечению ВИЧ-инфекции и СПИДа у взрослых. 2008-2009. Университет Джонса Хопкинса, 2008-2009 г. Available at http://www.eurasiahealth.org/attaches/82726/Bartlett_ pocketguide-2008.pdf
  8. Buchholz В., Beichert M., Marcus U. et al. German-Austrian recommendations for HIVl-therapy in pregnancy and in HIVl-exposed newborn, update 2008. Eur. J. Med. Res. 2009; 14 (11): 461-479.
  9. Naver L., Bohlin A.B., Albert J. et al. Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish recommendations 2007. Scand. J. Infect. Dis. 2008; 40 (6-7): 451-461.
  10. Clumeck N., Dedes N., Pozniak A., Raffi F. and the EACS Executive Commitee. European AIDS clinical society guidelines. Clinical management and treatment of HIV infected adults in Europe. Version 5-2. Available from: http://www.europeanaidsclinicalsociety.org/ guidelinespdf/l_Treatment_of_HIV_Infected_Adults.pdf.
  11. Афонина Л.Ю., Воронин Е.Е., Фомин Ю.А. и др. Клинические рекомендации по профилактике передачи ВИЧ-инфекции от матери ребенку. М., 2009.
  12. Sonne L., Mommeja-Marin Н., Hinkle J. et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J. Infect. Dis. 2005; 191: 825-829.
  13. Fundaro C., Genovese O., Rendeli С. et al. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS. 2002; 16: 299-300.
  14. Robinson B.S., Riccardi K.A., Gong Y. et al. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob Agents Chemother. 2000; 44 (8): 2093-2099.
  15. Colonno R., Rose R., McLaren С. et al. Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens. J. Infect Dis. 2004. 15; 189 (10): 1802-1810.
  16. Государственный реестр лекарственных средств Российской Федерации. Атазанавир. Типовая клинико-фармакологическая статья. Available at http:// www.regmed.ru/ InstrShow2 .asp?InstrLinkNx=a62ba62b a09ba60b
  17. European Medicines Agency. REYATAZ: summary of product characteristics. Available at http://www.ema.europa.eu/ humandocs/PDFs/EPAR/reyataz/586503en6.pdf
  18. Croom С. et al. Atazanavir. A review of its use in the management of HIV-1 infection. Drugs. 2009; 69 (8): 1107-1140.
  19. Stek A.M. Antiretroviral medications during pregnancy for therapy or prophylaxis. Curr HIV/AIDS Rep. 2009; 6 (2): 68-76.
  20. Shehata K., Nelson-Piercy C. Drugs to avoid. Best. Pract. Res. Clin. Obstet. Gynaecol. 2001; 15 (6): 971-986.
  21. Antiretroviral pregnancy registry seering committee. Antiretroviral pregnancy registry international interim report for 1 January 1989 through 31 January 2010. Wilmington, NC: Registry Coordinating Center; 2010. Available from URL: www.APRegistry.com.
  22. Stika C.S., Frederiksen M.C. Drug therapy in pregnant and nursing women. In: Atkinson A.J. ed. Principles of clinical pharmacology. San Diego (CA): Academic Press, 2001.
  23. Loebstein R., Lalkin A., Koren G. Pharmacokinetic changes during pregnancy and their clinical relevance. Clin. Pharmacokinet. 1997; 33: 328-343.
  24. Mirochnick M., Capparelli E. Pharmacokinetics of antiretrovirals in pregnant women. Clin. Pharmacokinet. 2004; 43: 1071-1087.
  25. Villani P., Floridia M,. Pirillo M.F. et al. Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and non pregnant women. Br. J. Pharmacol. 2006; 62: 309-315.
  26. Stek A.M., Mirochnick M., Capparelli E. et al. Reduced lopinavir exposure during pregnancy. AIDS. 2006; 20: 1931-1939.
  27. Burger D.M., Hoetelmans R.M.W., Hugen P.W.H. et al. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1 infected patients on indinavir-containing triple therapy. Antiviral. Ther. 1998; 3: 315-320.
  28. Anderson P.L., Brundage R.C., Kakuda T.N. et al. CD4 response is correlated with peak plasma concentrations of indinavir in adults with undetectable human immunodeficiency virus ribonucleic acid. Clin. Pharmacol. Ther. 2002; 71: 280-285.
  29. Joshi A.S., Barrett J.S., Fiske W.D. et al. Population pharmacokinetics of efavirenz in phase II studies and relationship with efficacy. In: 30th Interscience conference on antimicrobial agents and chemotherapy. San Francisco, USA. 26-29 September 1999.
  30. Morgan D.J. Drug disposition in mother and foetus. Clin. Exp. Pharmacol. Physiol. 1997; 24: 869-873.
  31. Krauer В., Krauer F., Hytten F.E. Drug disposition and pharmacokinetics in the maternal-placental-fetal unit. Pharmacol. Ther. 1980; 10: 301-328.
  32. Perucca E., Crema A. Plasma protein binding of drugs in pregnancy. Clin. Pharmacokinet. 1982; 7: 336-332.
  33. Bristol-Myers Squibb Company. Reyataz® (atazanavir sulfate) capsules: US prescribing information. http://packageinserts. bms.com/pi/pi_reyataz.pdf
  34. Morris A., Juethner S., Theroux E. Atazanavir use in pregnancy. In: 3rd IAS conference on HIV pathogenesis and treatment. Rio de Janeiro. 2005. Abstract TuPe5.2P01.
  35. Natha M., Hay P., Taylor G. et al. Atazanavir use in pregnancy: a report of 33 cases. Presented at: 14th Conference on
  36. retroviruses and opportunistic infections. Los Angeles, CA, USA. 25-28 February 2007 (Poster 750).
  37. Lechelt M., Lyons F., Clarke A. et al. Human placental transfer of atazanavir: a case report. AIDS. 2006; 20: 307.
  38. Ripamonti D., Cattaneo D., Maggiolo F.et al. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. AIDS. 2007; 21: 2409-2415.
  39. Eley Т., Vandeloise E., Child M. et al. Steady state pharmacokinetics and safety of atazanavir after treatment with ATV 300 mg once daily/ritonavir 100 mg once daily + zdv/3tc during the third trimester in hiv+ women. In: 15th Conference on retroviruses and opportunistic infections. Boston, MA, USA. 3-6 February 2008 (Poster 624).
  40. Mirochnick M., Stek A., Capparelli E. et al. Atazanavir pharmacokinetics with and without tenofovir during pregnancy. Presented at: 16th conference on retroviruses and opportunistic infections. Montreal, Canada. 8-11 February 2009 (Poster 941).
  41. Eley Т., Child M., Wang Y. et al. Steady state pharmacokinetics of atazanavir/ritonavir during pregnancy in hiv+ women. In: 47th Conference of infectious diseases society of America. Philadelphia, PA, USA. 29 October - 1 november 2009 (Poster 272).
  42. Conradie F., Zorilla C., Josipovic D. et al. The safety, efficacy and steady state pharmacokinetics of atazanavir/ritonavir once daily during pregnancy: results of the study AI424182. In: 5th International AIDS society conference on HIV pathogenesis, treatment and prevention. Cape Town, South Africa. 19-22 July 2010.
  43. Roustit M., Jlaiel M., Leclercq P., Stanke-Labesque F. Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women. Br. J. Clin. Pharmacol. 2008; 66 (2): 179-195.
  44. Cleijsen R.M., van de Ende M.E., Kroon F.P. et al. Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice. J. Antimicrob. Chemother. 2007; 60 (4): 897-900.
  45. Pellegrin I., Breilh D., Ragnaud J.M. et al. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study). Antivir. Ther. 2006; 11: 421-429.
  46. Chappuy H., Tréluyer J.M., Rey E. et al. Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus. Am. J. Obstet. Gynecol. 2004; 191 (2): 558-562.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Bionika Media